Cellics Therapeutics utilizes Cellular Nanoparticle (CNP™) technology to create therapeutic nanoparticles that neutralize inflammatory cytokines and autoantibodies, addressing overactive immune responses. Their approach also restores immune function by targeting toxins and viruses, enhancing patient health outcomes.
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Overactive immune responses, driven by inflammatory cytokines and autoantibodies, contribute to various diseases. Current treatments often lack specificity and can suppress the entire immune system, leading to increased susceptibility to infections and other complications. There is a need for therapies that can selectively modulate the immune response and restore balance without causing broad immunosuppression.
Solution
Cellics Therapeutics develops Cellular Nanoparticles (CNP™), a technology platform for creating therapeutic nanoparticles with cell membranes, also known as Cellular Nanosponges. These nanosponges are designed to neutralize inflammatory cytokines and autoantibodies, thereby cooling down overactive immune systems. The CNP™ technology can also restore immune function by neutralizing toxins and viruses. This approach aims to address significant unmet needs in inflammation and immunology by offering a more targeted and balanced approach to immune modulation.
Target Audience
The primary target audience includes patients with autoimmune and inflammatory diseases, as well as those with compromised immune systems due to toxins or viral infections.
Features
- Cellular Nanoparticle (CNP™) technology platform utilizing cell membranes to create therapeutic nanoparticles.
- Cellular Nanosponges designed to neutralize inflammatory cytokines and autoantibodies.
- Ability to restore immune function by neutralizing toxins and viruses.
- Targeted approach to modulate the immune response without broad immunosuppression.